EH
ACAD icon

Equitable Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Equitable Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,700
Closed -$368K – 623
2020
Q1 		$368K Sell
8,700
-1,050
-11% -$43.3K 0.01% 418
2019
Q4 		$417K Buy
+9,750
New +$424K 0.01% 437

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Equitable Holdings's ACAD Position: Q2 2020 in Review

Equitable Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 8,700 shares — an estimated $368K sold.

Equitable Holdings first reported a position in ACAD in Q4 2019 and held it in 2 quarters. The position peaked at $417K in Q4 2019. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • Equitable Holdings reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Equitable Holdings sold 8,700 Acadia Pharmaceuticals shares in Q2 2020, an estimated $368K.
  • Equitable Holdings first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Equitable Holdings's Acadia Pharmaceuticals position peaked at $417K in Q4 2019.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Equitable Holdings's 13F filing for Q2 2020, filed 13 Aug 2020.